"10.1371_journal.pone.0036153","plos one","2012-04-27T00:00:00Z","Michael Erb; Barbara Hoffmann-Enger; Holger Deppe; Michael Soeberdt; Roman H Haefeli; Christian Rummey; Achim Feurer; Nuri Gueven","Santhera Pharmaceuticals, Liestal, Switzerland; Biozentrum, University of Basel, Basel, Switzerland","Conceived and designed the experiments: ME NG. Performed the experiments: ME RHH. Analyzed the data: ME CR NG. Contributed reagents/materials/analysis tools: BH HD MS AF. Wrote the paper: AF NG. Contributed reagents, designed and synthesized compounds: BH HD MS AF.","The authors have read the journals policy and have the following conflicts: During the preparation of this manuscript, all authors were paid employees of Santhera Pharmaceuticals (Switzerland). Santhera is marketing Catena® (Idebenone) for the treatment of Friedreichs Ataxia in Canada and develops Catena for several other mitochondrial and neuromuscular indications. Compounds # 1, 3–5, 7, 9–14, 16–35, 53–57, 60–71 are subject of two international patent applications (WO/2012/022467 and WO/2012/022468). This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","04","Michael Erb","ME",8,TRUE,2,2,3,2,TRUE,TRUE,FALSE,0,NA,FALSE
